CO4960642A1 - Inhibidores de proteino farnesil transferasas inhibidores de la proteinofarnesiltransferasa y composicio nes que los ocntienen - Google Patents
Inhibidores de proteino farnesil transferasas inhibidores de la proteinofarnesiltransferasa y composicio nes que los ocntienenInfo
- Publication number
- CO4960642A1 CO4960642A1 CO97028769A CO97028769A CO4960642A1 CO 4960642 A1 CO4960642 A1 CO 4960642A1 CO 97028769 A CO97028769 A CO 97028769A CO 97028769 A CO97028769 A CO 97028769A CO 4960642 A1 CO4960642 A1 CO 4960642A1
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitors
- transferasas
- proteinofarnesil
- farnesil
- composition
- Prior art date
Links
- 229950008696 farnesil Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000003558 transferase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910017711 NHRa Inorganic materials 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611096P | 1996-05-22 | 1996-05-22 | |
| US3366296P | 1996-12-17 | 1996-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4960642A1 true CO4960642A1 (es) | 2000-09-25 |
Family
ID=26688183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97028769A CO4960642A1 (es) | 1996-05-22 | 1997-05-26 | Inhibidores de proteino farnesil transferasas inhibidores de la proteinofarnesiltransferasa y composicio nes que los ocntienen |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0938494A1 (enExample) |
| JP (1) | JP2000511527A (enExample) |
| CN (1) | CN1219174A (enExample) |
| AU (1) | AU728477B2 (enExample) |
| BG (1) | BG102936A (enExample) |
| BR (1) | BR9709354A (enExample) |
| CA (1) | CA2253934A1 (enExample) |
| CO (1) | CO4960642A1 (enExample) |
| CZ (1) | CZ376498A3 (enExample) |
| EA (1) | EA199801031A1 (enExample) |
| EE (1) | EE9800408A (enExample) |
| GE (1) | GEP20012500B (enExample) |
| IL (1) | IL126833A0 (enExample) |
| NO (1) | NO985405L (enExample) |
| NZ (1) | NZ332712A (enExample) |
| PL (1) | PL330120A1 (enExample) |
| SK (1) | SK161098A3 (enExample) |
| WO (1) | WO1997044350A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5968965A (en) * | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000504017A (ja) * | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| JP2000504014A (ja) * | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| US6028201A (en) * | 1996-01-30 | 2000-02-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
| US6265382B1 (en) * | 1997-04-11 | 2001-07-24 | Warner-Lambert Company | Dipeptide inhibitors of protein farnesyltransferase |
| US6737410B1 (en) | 1997-04-11 | 2004-05-18 | Warner-Lambert Company | Inhibitors of protein farnesyl transferase |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| AU759492B2 (en) * | 1998-04-27 | 2003-04-17 | Warner-Lambert Company | Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6632818B2 (en) | 2000-01-12 | 2003-10-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2002188646A (ja) * | 2000-12-20 | 2002-07-05 | Nsk Ltd | 転がり軸受及び軸受装置 |
| US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
| WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
| PE20070427A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| ES2431163T3 (es) | 2007-03-01 | 2013-11-25 | Novartis Ag | Inhibidores de PIM quinasa y métodos para su uso |
| ES2452349T3 (es) | 2007-05-21 | 2014-04-01 | Novartis Ag | Inhibidores de CSF-1R, composiciones, y métodos de uso |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
| EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CN103080093A (zh) | 2010-03-16 | 2013-05-01 | 达纳－法伯癌症研究所公司 | 吲唑化合物及其应用 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2699568A1 (en) | 2011-04-21 | 2014-02-26 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| CA2172125A1 (en) * | 1993-09-30 | 1995-04-06 | S. Jane Desolms | Inhibitors of farnesyl-protein transferase |
| EP0730605A1 (en) * | 1993-11-05 | 1996-09-11 | Warner-Lambert Company | Substituted di- and tripeptide inhibitors of protein:farnesyl transferase |
| US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
-
1997
- 1997-04-29 IL IL12683397A patent/IL126833A0/xx unknown
- 1997-04-29 CN CN97194835A patent/CN1219174A/zh active Pending
- 1997-04-29 BR BR9709354A patent/BR9709354A/pt not_active Application Discontinuation
- 1997-04-29 JP JP09542369A patent/JP2000511527A/ja not_active Abandoned
- 1997-04-29 GE GEAP19974612A patent/GEP20012500B/en unknown
- 1997-04-29 NZ NZ332712A patent/NZ332712A/xx unknown
- 1997-04-29 WO PCT/US1997/006591 patent/WO1997044350A1/en not_active Ceased
- 1997-04-29 AU AU28058/97A patent/AU728477B2/en not_active Ceased
- 1997-04-29 EA EA199801031A patent/EA199801031A1/ru unknown
- 1997-04-29 SK SK1610-98A patent/SK161098A3/sk unknown
- 1997-04-29 EE EE9800408A patent/EE9800408A/xx unknown
- 1997-04-29 CZ CZ983764A patent/CZ376498A3/cs unknown
- 1997-04-29 PL PL97330120A patent/PL330120A1/xx unknown
- 1997-04-29 EP EP97922365A patent/EP0938494A1/en not_active Withdrawn
- 1997-04-29 CA CA002253934A patent/CA2253934A1/en not_active Abandoned
- 1997-05-26 CO CO97028769A patent/CO4960642A1/es unknown
-
1998
- 1998-11-19 BG BG102936A patent/BG102936A/bg unknown
- 1998-11-20 NO NO985405A patent/NO985405L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU728477B2 (en) | 2001-01-11 |
| JP2000511527A (ja) | 2000-09-05 |
| CN1219174A (zh) | 1999-06-09 |
| CZ376498A3 (cs) | 1999-02-17 |
| BR9709354A (pt) | 1999-08-10 |
| EA199801031A1 (ru) | 1999-06-24 |
| NZ332712A (en) | 2000-07-28 |
| AU2805897A (en) | 1997-12-09 |
| CA2253934A1 (en) | 1997-11-27 |
| SK161098A3 (en) | 2000-06-12 |
| EP0938494A1 (en) | 1999-09-01 |
| EE9800408A (et) | 1999-06-15 |
| PL330120A1 (en) | 1999-04-26 |
| WO1997044350A1 (en) | 1997-11-27 |
| BG102936A (bg) | 1999-09-30 |
| NO985405L (no) | 1999-01-19 |
| IL126833A0 (en) | 1999-08-17 |
| NO985405D0 (no) | 1998-11-20 |
| GEP20012500B (en) | 2001-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4960642A1 (es) | Inhibidores de proteino farnesil transferasas inhibidores de la proteinofarnesiltransferasa y composicio nes que los ocntienen | |
| CO5150173A1 (es) | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv | |
| DK0725788T3 (da) | 2'-amido- og 2'-peptidomodificerede oligonukleotider | |
| ATE342927T1 (de) | Nicht-elastomere polyurethanzusammensetzungen | |
| ATE249466T1 (de) | Silizium enthaltender kettenverlängerer | |
| DK0659174T3 (da) | Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler | |
| ATE159945T1 (de) | Beta-aminoalkyl und beta-n- peptidylaminoalkylborsäure | |
| FI951630A0 (fi) | Infrapuna-väriaineella merkityt nukleotidit ja niiden käyttö nukleiinihappojen osoittamiseksi | |
| ES2128535T3 (es) | Nucleosidos y oligonucleotidos con grupos 2'-eter. | |
| ATE334666T1 (de) | Neue fettsäureanaloge zur behandlung der fettleber | |
| ES2156994T3 (es) | Sustratos para beta-lactamasa y usos de estos sustratos. | |
| BR9915679A (pt) | Composições e métodos para aumentar a mineralização óssea | |
| TR199901674T2 (enExample) | ||
| ATE516062T1 (de) | Quaternäre ammoniumverbindungen enthaltende wasserfreie zusammensetzungen | |
| ATE69239T1 (de) | Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung. | |
| BR9804309A (pt) | Tensoativos | |
| EP0973518A4 (en) | SEMISYNTHETIC METHOD FOR PRODUCING DIDEMNINE ANALOGS | |
| DE60214704D1 (de) | Polysiloxane und weitere polymere enthaltende zusammensetzungen | |
| DK0904270T3 (da) | Dihydrobenzofuran og beslægtede forbindelser anvendelige som antiinflammatoriske midler | |
| DE69815380D1 (de) | N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind | |
| ES2146911T3 (es) | Peroxiacidos. | |
| RO116856B1 (ro) | Compoziţie erbicidă, lichidă, pe bază de n-(fosfonometil)glicină | |
| ATE224398T1 (de) | Phosphorsäureester | |
| DE3768469D1 (de) | N-substituierte, estergruppen enthaltende acrylamide. | |
| ES2192090T3 (es) | Derivados de calixarenos. |